Search results
Sep 24, 2022 · This document presents a process to assess and control elemental impurities in the drug product using the principles of risk management as described in ICH Q9. This process provides a platform for developing a risk-based control strategy to limit elemental impurities in the drug product.
guideline: the evaluation of the toxicity data for potential elemental impurities; the establishment of a Permitted Daily Exposure (PDE) for each element of toxicological concern; and application of a risk-based approach to control elemental impurities in drug products.
- 843KB
- 85
This chapter specifies limits for the amounts of elemental impurities in drug products, such as arsenic, cadmium, lead, and mercury. It also provides options for demonstrating compliance, routes of exposure, and speciation of the impurities.
- 85KB
- 3
This document is a draft version of the ICH guideline for elemental impurities in pharmaceutical products, under public consultation until 25 December 2020. It contains extracts of the guideline with revisions to the PDEs for gold, silver and nickel, and a new appendix for gold.
- 369KB
- 23
Sep 14, 2022 · Q3D(R2) – Guideline for Elemental Impurities International Council for Harmonisation; Draft Guidance for Industry September 2022 Download the Final Guidance Document Read the Federal Register...
This guidance provides recommendations for controlling elemental impurities in human drug products based on ICH Q3D and USP General Chapters. It covers new and existing drug products, changes in specifications, and documentation requirements.
ICH Q3D(R2): Cutaneous PDEs and error corrections. Table of Contents. Summary of limits for elemental impurities (EI) by the cutaneous and transcutaneous route. Error correction of silver (Ag) PDE by oral route exposure. Error corrections of the gold (Au) PDEs by oral, parenteral and inhalation routes exposure.
